Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 2Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 33Carcinoma, Hepatocellular 27Neoplasms 19Colorectal Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Prostatic Neoplasms 12Lung Neoplasms 12Colonic Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Rectal Neoplasms 10Neoplasm Metastasis 8Leukemia 8Pancreatic Neoplasms 7NSCLC 6Multiple Myeloma 6Liver Neoplasms 6Esophageal Neoplasms 6Glioblastoma 5Small Cell Lung Carcinoma 4Recurrence 4Polycystic Ovary Syndrome 4Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Head and Neck Neoplasms 4Gestational Trophoblastic Disease 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Differentiated Thyroid Cancer × Clear all
NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡